Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2

Journal of the American College of Cardiology

Volumn 70, Issue 20, 2017, Pages 2552-2565

  Chang, Hui Ming ^a   Okwuosa, Tochukwu M ^b   Scarabelli, Tiziano ^c   Moudgil, Rohit ^d   Yeh, Edward T H ^a  

^a University of Missouri   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer therapy; cardiovascular complication; hypertension; radiation therapy; thromboembolism

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; APIXABAN; ARSENIC TRIOXIDE; BEVACIZUMAB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DABIGATRAN; DASATINIB; DEXAMETHASONE; DOCETAXEL; DOMPERIDONE; DOXORUBICIN; ENOXAPARIN; FLUOROURACIL; IMATINIB; IRINOTECAN; LENALIDOMIDE; LOPERAMIDE; MITOXANTRONE; PACLITAXEL; RETINOIC ACID; RIVAROXABAN; SUNITINIB; VORINOSTAT;

ANTICOAGULATION; ATRIAL FIBRILLATION; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DECISION MAKING; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; HEART BLOCK; HEART CATHETERIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERICARDITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; QT PROLONGATION; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSTHORACIC ECHOCARDIOGRAPHY; DISEASE MANAGEMENT; GLOBAL HEALTH; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; TRENDS;

CARDIOTOXICITY; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; MORBIDITY; NEOPLASMS;

EID: 85032696668     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.09.1095     Document Type: Review

References (151)

1. Jain, M., Townsend, R.R., Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 9 (2007), 320–328.
2. Suter, T.M., Ewer, M.S., Cancer drugs and the heart: importance and management. Eur Heart J 34 (2013), 1102–1111.
3. Abi Aad, S., Pierce, M., Barmaimon, G., Farhat, F.S., Benjo, A., Mouhayar, E., Hypertension induced by chemotherapeutic and immunosuppresive agents: a new challenge. Crit Rev Oncol Hematol 93 (2015), 28–35.
4. Maitland, M.L., Bakris, G.L., Black, H.R., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102 (2010), 596–604.
5. Miller, K., Wang, M., Gralow, J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007), 2666–2676.
6. Miller, K.D., Chap, L.I., Holmes, F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005), 792–799.
7. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
8. Yang, J.C., Haworth, L., Sherry, R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003), 427–434.
9. Scappaticci, F.A., Skillings, J.R., Holden, S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007), 1232–1239.
10. Procopio, G., Verzoni, E., Gevorgyan, A., et al. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology 73 (2007), 204–209.
11. Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S., Nakajima, K., Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99 (2008), 159–165.
12. Ratain, M.J., Eisen, T., Stadler, W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006), 2505–2512.
13. Riechelmann, R.P., Chin, S., Wang, L., et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol 31 (2008), 182–187.
14. Burstein, H.J., Elias, A.D., Rugo, H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (2008), 1810–1816.
15. Motzer, R.J., Michaelson, M.D., Redman, B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006), 16–24.
16. Demetri, G.D., van Oosterom, A.T., Garrett, C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (2006), 1329–1338.
17. Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007), 115–124.
18. Motzer, R.J., Rini, B.I., Bukowski, R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006), 2516–2524.
19. Genentech Inc. Avastin (bavacizumab) label–prescribing information. 2016. Available at: https://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed December 6, 2016.
20. Amgen. Kyprolis (carfilzomib). Prescribing information. Available at: http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.ashx. Accessed May 1, 2017.
21. Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372 (2015), 142–152.
22. Moslehi, J.J., Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375 (2016), 1457–1467.
23. Kamba, T., McDonald, D.M., Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96 (2007), 1788–1795.
24. Dincer, M., Altundag, K., Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 40 (2006), 2278–2279.
25. Sane, D.C., Anton, L., Brosnihan, K.B., Angiogenic growth factors and hypertension. Angiogenesis 7 (2004), 193–201.
26. Veronese, M.L., Mosenkis, A., Flaherty, K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006), 1363–1369.
27. Steeghs, N., Gelderblom, H., Roodt, J.O., et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14 (2008), 3470–3476.
28. Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M., Suter, T.M., Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105 (2002), 1551–1554.
29. Voortman, J., Giaccone, G., Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer, 6, 2006, 129.
30. Perez, E.A., Rodeheffer, R., Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22 (2004), 3–9.
31. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
32. Chu, T.F., Rupnick, M.A., Kerkela, R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370 (2007), 2011–2019.
33. Izzedine, H., Derosa, L., Le Teuff, G., Albiges, L., Escudier, B., Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 26 (2015), 1128–1133.
34. Simonneau, G., Gatzoulis, M.A., Adatia, I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 (2013), D34–D41.
35. Bonderman, D., Wilkens, H., Wakounig, S., et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 33 (2009), 325–331.
36. Ballout, F.A., Manshad, A.S., Okwuosa, T.M., Pulmonary hypertension and cancer: etiology, diagnosis, and management. Curr Treat Options Cardiovasc Med, 19, 2017, 44.
37. Galie, N., Simonneau, G., The Fifth World Symposium on Pulmonary Hypertension. J Am Coll Cardiol 62 (2013), D1–D3.
38. Rasheed, W., Flaim, B., Seymour, J.F., Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33 (2009), 861–864.
39. Montani, D., Bergot, E., Gunther, S., et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125 (2012), 2128–2137.
40. Shah, N.P., Wallis, N., Farber, H.W., et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 90 (2015), 1060–1064.
41. Cortes, J.E., Saglio, G., Kantarjian, H.M., et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 34 (2016), 2333–2340.
42. Gornik, H.L., Gerhard-Herman, M., Beckman, J.A., Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 23 (2005), 5211–5216.
43. Dequanter, D., Lothaire, P., Berghmans, T., Sculier, J.P., Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol 15 (2008), 3268–3271.
44. Kim, S.H., Kwak, M.H., Park, S., et al. Clinical characteristics of malignant pericardial effusion associated with recurrence and survival. Cancer Res Treat 42 (2010), 210–216.
45. El Haddad, D., Iliescu, C., Yusuf, S.W., et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol 66 (2015), 1119–1128.
46. Labbe, C., Tremblay, L., Lacasse, Y., Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison. Curr Oncol 22 (2015), 412–416.
47. Plana, J.C., Galderisi, M., Barac, A., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27 (2014), 911–939.
48. Yeh, E.T., Tong, A.T., Lenihan, D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004), 3122–3131.
49. Filopei, J., Frishman, W., Radiation-induced heart disease. Cardiol Rev 20 (2012), 184–188.
50. Jaworski, C., Mariani, J.A., Wheeler, G., Kaye, D.M., Cardiac complications of thoracic irradiation. J Am Coll Cardiol 61 (2013), 2319–2328.
51. Heidenreich, P.A., Hancock, S.L., Lee, B.K., Mariscal, C.S., Schnittger, I., Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003), 743–749.
52. Maisch, B., Ristic, A., Pankuweit, S., Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 53 (2010), 157–163.
53. Maisch, B., Ristic, A.D., Pankuweit, S., Neubauer, A., Moll, R., Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 23 (2002), 1625–1631.
54. Chen, D., Zhang, Y., Shi, F., et al. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget 7 (2016), 52436–52441.
55. Yeh ET. MD Anderson Practices in Onco-Cardiology, 2016. Available at: https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/cardiology/research.html.
56. Yeh, E.T., Chang, H.M., Cancer and clot. J Am Coll Cardiol 70 (2017), 939–941.
57. Sorensen, H.T., Mellemkjaer, L., Olsen, J.H., Baron, J.A., Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 (2000), 1846–1850.
58. Spencer, F.A., Emery, C., Lessard, D., et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 21 (2006), 722–727.
59. Navi, B.B., Reiner, A.S., Kamel, H., et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70 (2017), 926–938.
60. Yusuf, S.W., Razeghi, P., Yeh, E.T., The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 33 (2008), 163–196.
61. Faruque, L.I., Lin, M., Battistella, M., et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One, 9, 2014, e101145.
62. Ranpura, V., Hapani, S., Chuang, J., Wu, S., Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49 (2010), 287–297.
63. Choueiri, T.K., Schutz, F.A., Je, Y., Rosenberg, J.E., Bellmunt, J., Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28 (2010), 2280–2285.
64. Dy, G.K., Adjei, A.A., Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63 (2013), 249–279.
65. Hurwitz, H.I., Saltz, L.B., Van Cutsem, E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29 (2011), 1757–1764.
66. Qi, W.X., Min, D.L., Shen, Z., et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 132 (2013), 2967–2974.
67. Sonpavde, G., Je, Y., Schutz, F., et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 87 (2013), 80–89.
68. Blom, J.W., Doggen, C.J., Osanto, S., Rosendaal, F.R., Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005), 715–722.
69. Jacobson, G.M., Kamath, R.S., Smith, B.J., Goodheart, M.J., Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 96 (2005), 470–474.
70. Anders, J.C., Grigsby, P.W., Singh, A.K., Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol, 1, 2006, 14.
71. Czaykowski, P.M., Moore, M.J., Tannock, I.F., High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 160 (1998), 2021–2024.
72. Yeh, E.T., Bickford, C.L., Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53 (2009), 2231–2247.
73. Carrier, M., Le Gal, G., Tay, J., Wu, C., Lee, A.Y., Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9 (2011), 653–663.
74. Rodeghiero, F., Elice, F., Thalidomide and thrombosis. Pathophysiol Haemost Thromb., 33(Suppl 1), 2003, 15–18.
75. Olsen, E.A., Kim, Y.H., Kuzel, T.M., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007), 3109–3115.
76. Duvic, M., Talpur, R., Ni, X., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007), 31–39.
77. Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22 (2008), 414–423.
78. Streiff, M.B., Holmstrom, B., Ashrani, A., et al. Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. J Natl Compr Canc Netw 13 (2015), 1079–1095.
79. Khorana, A.A., Kuderer, N.M., Culakova, E., Lyman, G.H., Francis, C.W., Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 (2008), 4902–4907.
80. Vasan, R.S., Sullivan, L.M., Wilson, P.W., et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 142 (2005), 393–402.
81. Kearon, C., Akl, E.A., Ornelas, J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
82. Lenihan, D.J., Kowey, P.R., Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist 18 (2013), 900–908.
83. Hennekens, C.H., Dyken, M.L., Fuster, V., Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997), 2751–2753.
84. Berger, J.S., Brown, D.L., Becker, R.C., Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 121 (2008), 43–49.
85. Musallam, K.M., Dahdaleh, F.S., Shamseddine, A.I., Taher, A.T., Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res 123 (2009), 679–686.
86. Baz, R., Walker, E., Karam, M.A., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17 (2006), 1766–1771.
87. Palumbo, A., Falco, P., Corradini, P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network. J Clin Oncol 25 (2007), 4459–4465.
88. Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005), 4050–4053.
89. Palumbo, A., Cavo, M., Bringhen, S., et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 29 (2011), 986–993.
90. Palumbo, A., Palladino, C., Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf 3 (2012), 255–266.
91. Lee, A.Y., Levine, M.N., Baker, R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003), 146–153.
92. Carrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A.A., Lee, A.Y., Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 134 (2014), 1214–1219.
93. Vedovati, M.C., Germini, F., Agnelli, G., Becattini, C., Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 147 (2015), 475–483.
94. Hijazi, Z., Hohnloser, S.H., Andersson, U., et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol 1 (2016), 451–460.
95. Mantha, S., Laube, E., Miao, Y., et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis 43 (2017), 166–171.
96. Haverkamp, W., Breithardt, G., Camm, A.J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21 (2000), 1216–1231.
97. Vorchheimer, D.A., What is QT interval prolongation?. J Fam Pract Suppl (2005), S4–S7.
98. Ghatalia, P., Je, Y., Kaymakcalan, M.D., Sonpavde, G., Choueiri, T.K., QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112 (2015), 296–305.
99. Sanguinetti, M.C., Mitcheson, J.S., Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26 (2005), 119–124.
100. Sanguinetti, M.C., Jiang, C., Curran, M.E., Keating, M.T., A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81 (1995), 299–307.
101. Soignet, S.L., Frankel, S.R., Douer, D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001), 3852–3860.
102. Yap, Y.G., Camm, A.J., Drug induced QT prolongation and torsades de pointes. Heart 89 (2003), 1363–1372.
103. Kruse, V., Somers, A., Van Bortel, L., De Both, A., Van Belle, S., Rottey, S., Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. J Clin Pharm Ther 39 (2014), 259–265.
104. Symonds, R.P., Gourley, C., Davidson, S., et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol 16 (2015), 1515–1524.
105. Haas, N.B., Manola, J., Ky, B., et al. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: results from ASSURE, ECOG 2805. Clin Cancer Res 21 (2015), 4048–4054.
106. Llovet, J.M., Ricci, S., Mazzaferro, V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
107. Wells, S.A. Jr., Robinson, B.G., Gagel, R.F., et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30 (2012), 134–141.
108. Flaherty, L., Hamid, O., Linette, G., et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J 20 (2014), 18–24.
109. Kim, P.Y., Ewer, M.S., Chemotherapy and QT prolongation: overview with clinical perspective. Curr Treat Options Cardiovasc Med, 16, 2014, 303.
110. Food, Drug Administration, Department of Health and Human Services. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70 (2005), 6113–6115.
111. Drew, B.J., Ackerman, M.J., Funk, M., et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 55 (2010), 934–947.
112. Ederhy, S., Cohen, A., Dufaitre, G., et al. QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol 4 (2009), 89–97.
113. Virani, S.A., Dent, S., Brezden-Masley, C., et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol 32 (2016), 831–841.
114. Gupta, A., Lawrence, A.T., Krishnan, K., Kavinsky, C.J., Trohman, R.G., Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 153 (2007), 891–899.
115. Lal, K.S., Tariq, R.Z., Okwuosa, T., Haemodynamic instability secondary to cardiac involvement by lymphoma. BMJ Case Rep, 2016, 2016 bcr2016215775.
116. Mohty, D., Damy, T., Cosnay, P., et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106 (2013), 528–540.
117. Okmen, E., Erdinler, I., Oguz, E., Akyol, A., Cam, N., An unusual cause of reflex cardiovascular syncope: vagal paraganglioma. Ann Noninvasive Electrocardiol 8 (2003), 173–176.
118. Paschalis-Purtak, K., Pucilowska, B., Prejbisz, A., Januszewicz, A., Cardiac arrests, atrioventricular block, and pheochromocytoma. Am J Hypertens 17 (2004), 544–545.
119. Schurmeyer, T.H., Engeroff, B., Dralle, H., von zur Muhlen, A., Cardiological effects of catecholamine-secreting tumours. Eur J Clin Invest 27 (1997), 189–195.
120. Owen, P.J., Lazarus, J.H., Morse, R.E., Unusual complications of thyroid carcinoma. Postgrad Med J 79 (2003), 55–56.
121. Ferlitsch, A., Kreil, A., Bauer, E., et al. Bradycardia and sinus arrest during percutaneous ethanol injection therapy for hepatocellular carcinoma. Eur J Clin Invest 34 (2004), 218–223.
122. Ghobrial, I.M., Rajkumar, S.V., Management of thalidomide toxicity. J Support Oncol 1 (2003), 194–205.
123. Kaur, A., Yu, S.S., Lee, A.J., Chiao, T.B., Thalidomide-induced sinus bradycardia. Ann Pharmacother 37 (2003), 1040–1043.
124. Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 51 (2008), e1–e62.
125. Enriquez, A., Biagi, J., Redfearn, D., et al. Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators. J Am Coll Cardiol EP 3 (2017), 50–56.
126. Streitner, F., Kuschyk, J., Veltmann, C., et al. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm. Cytokine 47 (2009), 166–172.
127. Hu, Y.F., Liu, C.J., Chang, P.M., et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 165 (2013), 355–357.
128. Erichsen, R., Christiansen, C.F., Mehnert, F., Weiss, N.S., Baron, J.A., Sorensen, H.T., Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med 7 (2012), 431–438.
129. Guzzetti, S., Costantino, G., Vernocchi, A., Sada, S., Fundaro, C., First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med 3 (2008), 227–231.
130. Guzzetti, S., Costantino, G., Fundaro, C., Systemic inflammation, atrial fibrillation, and cancer. Circulation, 106, 2002, e40 author reply e40.
131. Farmakis, D., Parissis, J., Filippatos, G., Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 63 (2014), 945–953.
132. Dutcher, J.P., Fisher, R.I., Weiss, G., et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3 (1997), 157–162.
133. Hak, L., Mysliwska, J., Wieckiewicz, J., Szyndler, K., Siebert, J., Rogowski, J., Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res 29 (2009), 327–332.
134. Leong, D.P., Caron, F., Hillis, C., et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood 128 (2016), 138–140.
135. Byrd, J.C., Brown, J.R., O'Brien, S., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371 (2014), 213–223.
136. Thompson, P.A., Levy, V., Tam, C.S., et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175 (2016), 462–466.
137. Lee, H.J., Chihara, D., Wang, M., Mouhayar, E., Kim, P., Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leuk Lymphoma 57 (2016), 2914–2916.
138. Asnani, A., Manning, A., Mansour, M., Ruskin, J., Hochberg, E.P., Ptaszek, L.M., Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology 3 (2017), 1–10.
139. Zamorano, J.L., Lancellotti, P., Rodriguez Munoz, D., et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2768–2801.
140. Darby, S.C., Cutter, D.J., Boerma, M., et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 76 (2010), 656–665.
141. Darby, S.C., McGale, P., Taylor, C.W., Peto, R., Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6 (2005), 557–565.
142. Darby, S.C., Ewertz, M., Hall, P., Ischemic heart disease after breast cancer radiotherapy. N Engl J Med, 368, 2013, 2527.
143. Verma, V., Shah, C., Mehta, M.P., Clinical Outcomes and Toxicity of Proton Radiotherapy for Breast Cancer. Clin Breast Cancer 16 (2016), 145–154.
144. Boero, I.J., Paravati, A.J., Triplett, D.P., et al. Modern Radiation Therapy and Cardiac Outcomes in Breast Cancer. Int J Radiat Oncol Biol Phys 94 (2016), 700–708.
145. Armstrong, G.T., Oeffinger, K.C., Chen, Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31 (2013), 3673–3680.
146. Heidenreich, P.A., Schnittger, I., Strauss, H.W., et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 25 (2007), 43–49.
147. Hancock, S.L., Tucker, M.A., Hoppe, R.T., Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270 (1993), 1949–1955.
148. Groarke, J.D., Tanguturi, V.K., Hainer, J., et al. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol 65 (2015), 573–583.
149. Gonzaga, A.T., Antunes, M.J., Post-radiation valvular and coronary artery disease. J Heart Valve Dis 6 (1997), 219–221.
150. Ong, D.S., Aertker, R.A., Clark, A.N., et al. Radiation-associated valvular heart disease. J Heart Valve Dis 22 (2013), 883–892.
151. Curigliano, G., Cardinale, D., Suter, T., et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23:Suppl 7 (2012), vii155–vii166.